Sort
17,288 grants matching “multiple sclerosis”
Signal transduction in neutrophil chemotaxis
$300,548Hongbo R Luo · Boston Children'S Hospital · R01 · FY2010 · GM
Muscarinic acetylcholine receptor subtypes: physiological roles
$300,504Jurgen Wess · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2017 · DK
Manual Control of the Upper Esophageal Sphincter
$300,476Peter Belafsky · University Of California At Davis · R01 · FY2014 · DK
CHEMOKINE RECEPTORS IN VASCULAR DISEASE
$300,470Oregon Health And Science University · R01 · FY2003 · HL
CHEMOKINE RECEPTORS IN VASCULAR DISEASE
$300,470Oregon Health And Science University · R01 · FY2001 · HL
CHEMOKINE RECEPTORS IN VASCULAR DISEASE
$300,470Oregon Health And Science University · R01 · FY2002 · HL
Imaging PTEN-induced changes in adult cortical structure and function in vivo
$300,339Joshua Trachtenberg · University Of California Los Angeles · R01 · FY2011 · MH
Neuroinflammation and Behavior in the Aged
$300,331Rodney W Johnson · University Of Illinois At Urbana-Champaign · R01 · FY2007 · AG
Anti-inflammatory mechanisms of American ginseng in colitis
$300,313Prakash S. Nagarkatti · University Of South Carolina At Columbia · P01 · FY2009 · AT
Molecular Analysis of Genes Uniquely Expressed by Encephalitogenic T Cells
$300,234Amy E Lovett-Racke · Ohio State University · R01 · FY2010 · NS
Imaging PTEN-induced changes in adult cortical structure and function in vivo
$300,156Joshua Trachtenberg · University Of California Los Angeles · R01 · FY2012 · MH
Mechanisms Regulating TNFAIP3 Gene Expression
$300,110Patrick M Gaffney · Oklahoma Medical Research Foundation · U19 · FY2017 · AI
Development of a Small Molecule Inhibitor for EBV Lytic Reactivation
$300,001Ursula D Ramirez · Vironika, Llc · R43 · FY2016 · AI
Nanoimmunotherapy for chronic immune-mediated diseases
$300,000David A Horwitz · General Nanotherapeutics, Llc · R41 · FY2022 · AI
MOLECULAR BASIS OF THEILER'S VIRUS-INDUCED DEMYELINATION
$300,000Evanston Hospital · R01 · FY2001 · NS
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease
$300,000Randolph J. Noelle · Immunext, Inc. · R41 · FY2012 · AI
Medicinal Chemistry Based Optimization of Lead Compounds Against Multiple Scleros
$300,000Antonio J Barbosa · Adhaere Pharmaceuticals, Inc. · R43 · FY2013 · AI
Targeted RNA degradation assay for new antiviral drug discovery
$300,000Ryan O'Hanlon · Lucerna, Inc. · R43 · FY2024 · AI
Long-acting VIP formulations for the treatment of chronic inflammatory diseases
$300,000Sandra Reichstetter · Pharmain Corporation · R43 · FY2010 · AI
Long-acting VIP formulations for the treatment of chronic inflammatory diseases
$300,000Sandra Reichstetter · Pharmain Corporation · R43 · FY2009 · AI
Immune Checkpoint-Engineered oligodendrocytes as treatment for multiple sclerosis
$300,000Andrew Zhuang Wang · Ut Southwestern Medical Center · R56 · FY2025 · AI
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease
$300,000Randolph J. Noelle · Immunext, Inc. · R41 · FY2013 · AI
Small Molecule Targeting of Viral Non-Coding RNA EBER1 to Detect and Treat Latent EBV
$300,000Ursula D Ramirez · Vironika, Llc · R43 · FY2018 · AI
N-acetylglucosamine analogs for the treatment of Multiple Sclerosis.
$300,000Ani Oganesyan · Glixis Therapeutics, Llc · R43 · FY2014 · AI
MOLECULAR BASIS OF THEILER'S VIRUS-INDUCED DEMYELINATION
$300,000Evanston Northwestern Healthcare · R01 · FY2003 · NS